海外の治験の状況「COVID-19」での検索結果
70件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulations of GlaxoSmithKline (GSK) Biologicals’ new generations meningococcal serogroups A, C, W-135, Y-tetanus toxoid conjugate (MenACWY-TT) vaccine versus one subcutaneous dose of MENCEVAX™ ACWY in healthy adolescents/young adults aged 15-19 years - MenACWY-TT-012
- Primary immunization of healthy adolescents/young adults against meningococcal disease due to Neisseria meningitidis (N. meningitidis) of serogroups A, C, W-135 and Y.
- Denmark
- 2005-04-08
Not Recruiting
- A 19-week, randomized, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate 50/100mcg BID, fluticasone propionate 100mcg BID and placebo on peripheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects
- Asthma
- United Kingdom
- 2007-06-26
Authorised
- Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase II study. NVALT 19
- Patients with histologically or cytologically proven malignant mesothelioma MedDRA version: 14.1 Level: LLT Classification code 10035605 Term: Pleural mesothelioma malignant advanced System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Netherlands
- 2013-05-17
Not Recruiting
- A phase III, observer-blind, multi-country, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals FLU NG vaccine compared to the reference vaccine Fluarix™ when administered to elderly subjects aged 66 years and older. - FLU NG-037 EXT:005 Y2
- Immunization against influenza in male and female subjects aged 66 years or older and 19-43 years of age.
- Belgium, Germany
- 2008-07-09
Not Recruiting
- Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III trial (AML-19)of the EORTC-LG and GIMEMA-ALWP
- Elderly patients (61-75 years not eligible for intensive chemotherapy;age > 75 years), with previously untreated, primary or secondary (no after other myeloproliferative diseases) AML (except M3). MedDRA version: 14.1 Level: PT Classification code 10000880 Term: Acute myeloid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2005-05-18
Not Recruiting
- A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1
- The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis.
- Germany
- 2006-10-17
Not Recruiting
- Cognitive-behavioural treatment for adolescents with PTSD and SUD
- Substance use disorders (SUD) # ICD-10 F10-19 Mental and behavioural disorders due to psychoactive substance use (excluding tobacco);F43.1 - Post-traumatic stress disorder
- Germany
- 2013-01-15
Recruiting
- BEAT: Binge-Eating Adolescent Treatment - a training program for adolescents with binge-eating
- The treatment program is conducted in a within-subject control design. Therefore, no control groups will be added to the study design for the treatment study. However, for the experimental paradigms, a healthy control group consisting of healthy adolescents, 14-19 years of age, without any mental disorder will be recruited. # Binge eating disorder;F50.8 - Other eating disorders
- Switzerland
- 2018-06-21
Not Recruiting
- Prospective, single-arm, multi-center, open-label study to investigate the potential to reduce concomitant antipsychotics use in subjects with moderate dementia of Alzheimer’s type [DAT] treated with memantine - MemAP
- Dementia of Alzheimer’s Type [DAT] in subjects with Mini Mental State Examination [MMSE] score 10-19 and Global Deterioration Scale [GDS] score 3-5 and antipsychotics medication during the last 3 months (at least intake at 5 days/week) MedDRA version: 10.1 Level: LLT Classification code 10012271 Term:
- Germany
- 2007-11-16
Authorised
- A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia - hLL2-18
- Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chronic lymphocytic leukemia, but has been described as a low-grade lymphoplasmacytic lymphoma characterized by its over production of monoclonal immunoglobulin M (IgM).
- Spain
- 2005-05-23
